Reference ranges for newer thyroid function tests in premature infants

Hypothyroxinemia in premature infants: is thyroxine treatment necessary?

The increased survival of very low birth weight (VLBW) premature infants has been associated with an increased prevalence of transient disorders of thyroid function during the early weeks of life. All VLBW infants have relatively low, and gestation age-dependent, thyroxine-binding globulin (TBG) concentrations associated with variably low total thyroxine (T4) concentrations. These infants also have a high prevalence (30%-60%) of nonthyroidal illnesses that impact thyroid function, including total and free iodothyronine concentrations. Finally, thyroid gland hormone biosynthesis and the hypothalamic-pituitary axis are relatively immature and thyroid glandular iodine stores are low. As a result, VLBW infants manifest a high prevalence of transient primary hypothyroidism (0.41%) and transient hypothalamic-pituitary (thyrotropin [TSH] deficiency) hypothyroidism (5%-10%?). Thyroid function should be monitored in VLBW infants during the first 1-4 weeks of life to detect these disorders as well as the much less common permanent congenital hypothyroidism. An elevated serum TSH level (> 20 mU/L) is diagnostic of primary hypothyroidism and a low free T4 concentration with a normal or low serum TSH level suggests hypothalamic-pituitary hypothyroidism. Treatment of transient or permanent primary hypothyroidism and of congenital TSH deficiency is indicated. Preliminary data suggests that 30-60-day treatment of transient hypothalamic-pituitary hypothyroidism improves IQ at 2 years of age. However, further information confirming the benefit of treatment, the threshold free T4 values for diagnosis, and the optimal dose of T4 are necessary.

Thyroid function in the preterm infant

Thyroid gland function develops and matures during fetal life, with production of serum thyroxine (T4) concentrations beginning around 12 weeks gestation and increasing to term. Infants born prior to term have lower cord serum T4 concentrations that correlate with gestational age or birth weight. This is partially the result of lower thyroxine-binding globulin (TBG) concentrations. The cord serum free thyroxine (FT4) concentrations also correlate with gestational age, but they are not proportionately as low as the cord T4 concentration. Preterm infants have a postnatal thyrotropin (TSH) surge and rise in serum T4 and triiodothyronine (T3), which is qualitatively similar to, but quantitatively smaller than, term infants. In contrast to term infants, preterm infants often experience a fall in serum T4 and T3 in the first week of life to below birth levels. This drop appears to be the result of many factors, including nutritional problems and decreased hepatic TBG production, immaturity of hypothalamic-pituitary control of the thyroid gland, immaturity of the thyroid gland itself, and increased tissue utilization of T4. These changes are impacted by complications of prematurity, such as respiratory distress syndrome (RDS), which result in nonthyroidal illness-like changes. Again, serum FT4 seems less affected, and when measured by equilibrium dialysis may be in the normal range for age. Several studies have correlated different measures of morbidity and mortality in the preterm infant with lower serum T4 concentrations. However, as with adults, it may be that low serum T4 concentrations are a marker of the sickest preemies. Also, as with adults, this has led to speculation that T4 treatment might be beneficial in improving these complications of prematurity, in particular the neurological outcome. While some studies appear to show improvement in some facet of medical complications with T4 treatment, most show no effect. Regarding neurological outcome, the 2 best controlled trials do not show improvement in neuropsychiatric testing outcome assessed up to 2 years of age. One study, however, showed an IQ that was 18 points higher in the T4-treated subgroup less than 27 weeks gestational age. It may be that the most preterm infants, eg, those less than 27 weeks of age, are at a disadvantage compared with their intrauterine counterparts, in that they lack the maternal thyroid hormone contribution and are forced to adapt to extrauterine life before their hypothalamic-pituitary-thyroid axis is mature enough to deal with tissue thyroxine demands. Further controlled studies are needed to determine if this subgroup of infants indeed may benefit from transient thyroid hormone supplementation.

Plasma thyroid hormones in premature infants: effect of gestational age and antenatal thyrotropin-releasing hormone treatment. TRH Collaborative Trial Participants

Thyroid hormones are important for both perinatal adaptation and long-term psychomotor development; however, there is limited information on the effects of extreme prematurity and antenatal TSH-releasing hormone (TRH) treatment on pituitary-thyroid function. In this study we assayed plasma triiodothyronine (T3) and TSH in infants who were part of a collaborative trial of antenatal maternal TRH therapy. Within the control population (n = 166), infants of 24-28-wk and 28-32-wk gestational age had comparable levels of T3 (0.94 and 1.06 nmol/L, respectively) and TSH (5.7 and 7.2 mU/L) at birth, but the increases at 2 h and subsequent T3 levels were less in the 24-28 wk versus 28-32-wk gestation infants. In the TRH-treated group (n = 131), T3 was lower in the first day for infants delivered 7-72 h after antenatal TRH compared with control infants. TSH at birth was approximately 3.5-fold greater for infants delivered at 0-6 h after the last TRH dose compared with the control group and was suppressed in infants delivering at 7-36 h. T3 and TSH levels were not different between control and TRH-treated groups at 3-28 d of age. In TRH stimulation tests on d 28, control and TRH-treated groups had similar peak levels of TSH and incidence of exaggerated response (TSH > or = 35 mU/L). We conclude that extremely premature infants have a reduced postnatal surge in TSH and T3 and maintain lower T3 concentrations, probably reflecting tertiary hypothyroidism. The stimulatory and suppressive effects of antenatal TRH treatment observed at birth are transient and do not affect pituitary-thyroid responsiveness at 28 d of age.

Neonatal skin and skin care

Infant skin differs from adult skin in several ways. These important differences place infants at increased risk for fluid electrolyte imbalance, thermal instability, skin damage, percutaneous infection, and percutaneous toxicity from topically applied agents. This article includes a review of skin development, as well as the details of current skin care practices in the neonatal nursery. A better understanding of the principles of infant skin care and a more uniform approach to skin care in the neonatal nursery can minimize risks and costs to this special population of patients.

Thyroxine screening values in premature infants

OBJECTIVES

Premature infants often have low thyroxine levels when compared to fullterm infants. We sought to determine gestational age specific normal ranges for thyroxine screening results for premature infants in neonatal intensive care units.

METHODS

Thyroid screening results for infants less than 38 weeks gestation admitted to two NICUs were examined. For each sample the thyroxine Z-score was computed using parameters from fullterm infants. The mean thyroxine Z-score was calculated for each gestational age for days of life 1, 2, 3-7, 8-14, 15-21, 22-28, and 29-60.

RESULTS

There were 1144 specimens obtained from 543 premature infants. The mean thyroxine Z-score was below 0 for almost every gestational age and days-of-life category. The mean thyroxine Z-score increased with gestational age, but did not rise with increasing postpartum age.

CONCLUSION

The data show that normal thyroxine Z-scores for premature infants are lower than for fullterm infants and remain low at least as long as the infants remain ill.

Thyroxine values from newborn screening of 919 infants born before 29 weeks' gestation

OBJECTIVES

Severe transient hypothyroxinemia in premature infants is associated with cerebral palsy and mental retardation: this study assessed its prevalence in very premature infants.

METHODS

Congenital hypothyroidism screening programs in three states provided thyroxine values for 919 newborn infants younger than 29 weeks who were enrolled in a multicenter study.

RESULTS

Thyroxine values were lower than 4.0 micrograms/dL in 21% of survivors and increased each week by 0.6 microgram/dL (95% confidence interval [CI] = 0.4, 0.7). At tests done 1 to 2 days after birth, levels were 2.5 micrograms/dL higher (95% CI = 1.8, 3.3) than at tests done at 8 to 14 days. In New York, levels were 1.0 microgram/dL higher (95% CI = 0.3, 1.6) than elsewhere. The levels of infants who died were 1.3 micrograms/dL lower (95% CI = 0.6, 2.0) than those of survivors.

CONCLUSIONS

Severe transient hypothyroxinemia is common in very premature infants and deserves further study.

Serum free thyroxine concentration is not reduced in premature infants with respiratory distress syndrome

OBJECTIVE

We used improved methods of assay to determine whether pituitary-thyroid function is altered in premature infants with respiratory distress syndrome (RDS) during the first week of postnatal life.

METHODS

Serum free thyroxine (T4) was measured by direct equilibrium dialysis, total thyroxine (TT4) by radioimmunoassay, and thyrotropin by a sensitive immunometric assay in 90 premature infants (45 healthy control subjects and 45 with RDS) during their first week of life after 25 to 30 weeks of gestation. Infants in the RDS group received exogenous surfactant therapy.

RESULTS

Free T4 and thyrotropin concentrations of infants were not significantly different between RDS and control groups. As expected, infants with RDS had significantly lower serum total T4 concentrations compared with control infants (p < 0.001). This difference was present even after stratification for gestational age (25- to 27-week group, p = 0.012; 28- to 30-week group, p = 0.002). Lower total T4 concentrations were attributable to lower T4 binding to serum proteins among infants with RDS compared with control subjects, especially in the 25- to 27-week gestation group (p = 0.0075).

CONCLUSION

These data indicate that pituitary-thyroid function is not altered in premature infants with RDS. The low total T4 state in these premature infants is attributable solely to reduced serum T4 binding, as is often seen in acute nonthyroidal illnesses.

Thyroid function tests and their interpretation

For general screening of children who are in fairly good health and in whom CNS or pituitary disease is not strongly suspected, the newer THS assays are very useful in assessing the action of both endogenous and exogenous thyroid hormone. Those children in whom primary hypothyroidism is strongly suspected or who are already on thyroid hormone supplementation, the free T4 assay provides a useful adjunct to the TSH. If Grave's disease or factious hyperthyroidism is suspected, the total T3 assay is a useful adjunct to the TSH and the free T4. The screening of possible hypothyroidism as a result of hypothalamic or pituitary disease, the free T4 is relied on heavily, along with the response of TSH to TRH stimulation. Measurement of the nocturnal TSH surge may also be useful in this situation.

Prediction of neonatal hyperthyroidism in infants born to mothers with Graves disease

OBJECTIVE

To determine whether determinations of thyrotropin-receptor antibody (TRAb) levels in newborn infants of women with Graves disease would predict which infants will have hyperthyroidism.

METHODS

The TRAb levels, assayed in the sera of 14 infants born to 14 women with Graves disease, were measured sequentially in the infants with hyperthyroidism during the course of antithyroid medication therapy.

RESULTS

Seven infants had TRAb values less than 0.15 and remained euthyroid. In seven infants whose initial TRAb values were more than 0.25 (range, 0.48 to 0.88), clinical and biochemical signs of hyperthyroidism developed. The infants were treated with antithyroid medication until day 57 to day 123 of life. Therapy was discontinued when the infants were free of symptoms and when serum thyroxine and triiodothyronine and free thyroxine levels remained normal during therapy with decreasing doses of antithyroid medication. When the medication was discontinued, TRAb values were less than 0.20.

CONCLUSIONS

Infants born to mothers with Graves disease with initial TRAb values less than 0.15 remained euthyroid. The TRAb values greater than 0.25 were associated with the development of neonatal hyperthyroidism. During treatment of neonatal hyperthyroidism, TRAb values less than 0.20 may be helpful in deciding when to withdraw antithyroid medication.